JPRN-jRCT2080225126已完成3 期
Biological equivalence study of 0.002% DE-117B Ophthalmic Solution and 0.002% Omidenepag Isopropyl Ophthalmic Solution in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Must have a diagnosis of POAG or OHT in both eyes, or one eye with POAG and the other with OHT.
- •- Corrected visual acuity (CVA) of 0.2 or better in each eye.
排除标准
- •- Females who are pregnant, nursing or planning a pregnancy.
- •- Subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period.
- •- Use of contact lenses within 2-3 weeks prior to Baseline until end of treatment in either eye
- •- Aphakia or pseudophakia in either eye
研究者
相似试验
尚未招募
不适用
Study of absorption and elimination rate of Desloratadine 5-mg tablets in comparison with Desloratadine brand tablets (Clarinex®).IRCT20200407046981N50Behestan Pharmaceutical Company24
尚未招募
1 期
An Open Label, Crossover Bioequivalence Study of DALAVIR Tablets of the Government Pharmaceutical Organization, Thailand with TIVICAY (Dolutegravir 50 mg tablets) +EPIVIR (Lamivudine 300 mg tablets) VIREAD (Tenofovir disoproxil fumarate 300 mg tablets) in Healthy Subjects under Fasting ConditionsHealthy male and female subjectsBioequivalence fed conditionsTCTR20220331004The Government Pharmaceutical Organization52
尚未招募
1 期
An Open Label, Crossover Bioequivalence Study of DALAVIR Tablets of the Government Pharmaceutical Organization, Thailand with TIVICAY (Dolutegravir 50 mg tablets) +EPIVIR (Lamivudine 300 mg tablets) VIREAD (Tenofovir disoproxil fumarate 300 mg tablets) in Healthy Subjects under Fasting ConditionsHealthy male and female subjectsBioequivalence fed conditionsTCTR20210913002The Government Pharmaceutical Organization52
已完成
Unknown
Budesonide tablet bioequivalenceBioequivalence study in healthy volunteers.IRCT20130313012810N23Tasnim pharmaceutical Company24
招募中
不适用
Study of absorption and elimination rate of Ursodeoxycholic acid 300-mg Capsule in comparison with Ursodeoxycholic acid brand Capsule (Ursoflor®).Bioequivalence study.IRCT20200407046981N22Ahran Tejarat pharmaceutical Co24